MedTrace Logo

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-01-28

No results posted yet for this study

Summary

This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

ADA-011

ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.

DRUG

PD(L)-1 inhibitor

PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.

Sponsors & Collaborators

  • Adanate, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-10-30
Completion
2024-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05601219 on ClinicalTrials.gov